Intratus, Inc. is a privately held, clinical-stage life sciences company dedicated to the development of its patented, novel non-invasive drug delivery platform technologies.
The Intratus portfolio is focused on the treatment of a multitude of ophthalmic diseases in all segments of the eye. Additionally, the platform technology extends to systemic diseases such as cardiovascular disease, diabetes and allergy & immunology.
The company’s IP portfolio provides the foundation for monetizing its internally discovered R & D assets. Intratus is presently headquartered in San Diego, California with operational capacity in the U.S.A., Europe, Asia and South America.
The Mission of Intratus, Inc. is to bring innovative drug delivery technology to patients.
Intratus, Inc. seeks to cause a paradigm shift within drug delivery. Its elegant drug delivery solution provides significantly greater clinical effects as well as significantly lower adverse events. The result; patients receive what they have desired for decades and Intratus partners and investors are rewarded.
OUR INNOVATIVE TECHNOLOGY
Intratus, Inc. has developed a diverse portfolio of sustained drug delivery formulations and technologies that can be used to deliver a broad array of drugs that include; new molecules, generic or orphaned drugs, underutilized drugs or those drugs possessing a poor adverse events profile. The Intratus technology provides optimized delivery of medications to target tissues.
Chief Executive Officer
Aaron Dyer is the Chief Executive Officer and one of the two co-founders of Intratus, Inc. He, in addition to Padma Nanduri, M.D., F.A.C.S. co-invented and developed Intratus’s drug delivery technologies and formulations. Mr. Dyer serves as President and Chairman of the Board of Directors for Intratus, Inc. Prior to founding Intratus, Mr. Dyer cofounded the nation’s first internet mortgage lender of “A grade” mortgage investments, which grew from one county to servicing thirty seven states before its acquisition by a top five bank in the United States. Prior to working in the mortgage industry, he served as a Corporate Vice President at Stewart Enterprises. During his tenure, Stewart Enterprises grew rapidly from serving three states in the United States to becoming a publicly held, multinational company. Prior to corporate life, Mr. Dyer received a full ROTC scholarship to the United States Air Force Academy.
PADMA NANDURI, M.D., F.A.C.S.
Chief Medical Officer
Padma Nanduri, M.D. F.A.C.S. is a Board Certified Ophthalmologist and is one of the two co-founders of Intratus, Inc. She, in addition to Aaron Dyer, invented and developed the Intratus drug delivery technologies and formulations. Dr. Nanduri is Chief Medical Officer, Corporate Vice President, and serves on the Board of Directors. She was a resident and Chief Resident and graduated Ophthalmology residency from Saint Louis University and did a fellowship in ocular surgery on Project Orbis in New York, New York.
Dr. Nanduri attended the University of Rochester School of Medicine and Dentistry and graduated with a “Doctor of Medicine with Distinction in Research” Degree. She won the Spencer Award in Organic Chemistry as an undergraduate at Syracuse University where, thru an NIH grant, she led research in synthesizing compounds to neutralize the HIV virus at the height of the HIV epidemic. Dr. Nanduri also double majored in Communications and worked at an NBC affiliate investigative team producing a multi part series on earmarks in the New York State Senate that won an award by Broadcasting Magazine. Additionally, She was a candidate for the Rhodes Scholarship. Prior to attending Syracuse University, she was one of twenty high school students in the United States accepted into an Six Year Accelerated Combined Bachelors and Medical Degree Program at the Rensselaer Polytechnic Institute and Albany Medical College. In medical practice, Dr. Nanduri built a private practice specializing in comprehensive ophthalmology including anterior segment disorders such as cataract and Lasik surgery and dry eye. While in private practice, she worked as a general medical contributor for biweekly news segments for NBC news. In patient care, she won the Po’Okele patient care Award voted by patients for quality of care.
INTRATUS ADVISORY BOARD
JOHN DUNN, ESQ.
Strategic and New Venture Advisor
Mr. Dunn recently retired from Biogen Idec where he was an Executive Vice President and headed up their corporate venture group which managed a $200 million fund for strategic investments in emerging biotech companies. Prior to the merger of IDEC Pharmaceuticals and Biogen, Mr. Dunn was Senior Vice President and General Counsel of IDEC. He led IDEC’s legal and compliance departments and served as a member of the company’s senior management team.
ROBERT J. CIONNI, M.D.
Robert J. Cionni, M.D. is the Medical Director of The Eye Institute of Utah and a world-renowned expert in the field of modern cataract surgery. He is a board-certified ophthalmologist, specializing in cataract surgery, lens implants, and refractive surgeries such as LASIK, PRK, implantation of ICLs and refractive lens exchange. He has established himself as a leader in his specialty by pioneering some of the most advanced cataract and implant techniques, authoring numerous articles and textbook chapters about specialized cataract techniques, technologies and management of complications. He is actively involved in clinical research bringing the latest technologies to his patients; sometimes, well before these technologies are available to other surgeons.
ERIC DONNENFELD, M.D.
Eric Donnenfeld, MD was a resident and Chief Resident at Manhattan Eye, Ear and Throat Hospital and he completed a Cornea Fellowship at Wills Eye Hospital in 1985. He is a trustee of Dartmouth Medical School and a clinical professor of ophthalmology at NYU. He has written over 200 peer review papers on cornea, external disease, cataract and refractive surgery, and 40 book chapters and books. He is on the editorial board of 9 journals and has participated in over 60 FDA studies. He was a primary investigator of both the excimer laser and femtosecond laser for cataract surgery. He is a Fellow of the American Academy of Ophthalmology and has received its Honor Award, Senior Honor Award, Life Time Achievement Award, and Secretariat Award. Dr. Donnenfeld is a National Medical Director of TLC laser centers and Surgical Director of the Lions Eye Bank for Long Island. Dr. Donnenfeld served as president of many professional societies including the Nassau Surgical Society, cornea section of ASCRS, the Ophthalmology Division of the Nassau Academy of Medicine, and the International Ocular Microbiology and Immunology Group. He is the past president of ASCRS and is in the presidential succession line for the International Intraocular Implant Society. Dr. Donnenfeld is the editor-in-chief of EyeWorld.
Edward Holland, MD is the Director of Cornea Services at Cincinnati Eye Institute and Professor of Ophthalmology at the University of Cincinnati. He attended the Loyola-Stritch School of Medicine in Chicago and trained in Ophthalmology at the University of Minnesota. He completed a fellowship in cornea and external disease at the University of Iowa, and then completed a second fellowship in ocular immunology at the National Eye Institute, National Institutes of Health in Bethesda, Maryland. He returned to serve as Director of Cornea and Refractive Surgery Service at the University of Minnesota. He was promoted to the position of Professor and was granted the Elias Potter Lyon Chair in Ophthalmology. He also served as President of the Minnesota Academy of Ophthalmology. Dr. Holland formerly served as the President for the American Society of Cataract and Refractive Surgery from 2011-2012. He was also a member of the Executive Committee and now serves as the Program Chair. Dr. Holland was a former member of the Board of Trustees for the American Academy of Ophthalmology. He has also been the Secretariat of the Annual Meeting for the American Academy of Ophthalmology. He was awarded the Life Achievement Honor Award at the 2012 American Academy of Ophthalmology Annual Meeting. Dr. Holland has served as the Chair of the Eye Bank Association and was the former Chair of the Medical Advisory Board for the Eye Bank Association of America. He is the past President of the Cornea Society and previously served many years on its Board of Directors. Dr. Holland has been awarded the Castroviejo Award from the Cornea Society in 2013. He has also received both the Senior Achievement Award and The Honor Award from the American Academy of Ophthalmology. He was awarded the Binkhorst Medal by the American Society of Cataract and Refractive Surgery in 2008. He was a recipient of the 2002 Paton Society Award given by the Eye Bank Association of America. Among other honors, Dr. Holland has been listed in the "Best Doctors in America." He has a national and international reputation for his knowledge and expertise in the field of cornea and external disease. He is frequently invited to give lectures both nationally and internationally. Dr. Holland is the author of over 270 articles in peer review journals and has edited Cornea, the most widely read textbook on corneal disease and surgery. As the Director of Cornea Services at the Cincinnati Eye Institute, Dr. Holland has attracted worldwide referrals for medical and surgical corneal problems and for stem cell transplantation. His clinical interests include Corneal Transplantation, Cataract Surgery and Ocular Surface Transplantation.
STEPHEN SLADE, M.D.
Stephen Slade, M.D., a specialist in Presbyopia correction, cataract surgery, LASIK, Implantable Contact Lenses, and refractive surgery, is a Houston native whose private practice is in Houston, Texas. He attended Tulane University and the University of Texas Medical School with a final, elective year spent at Guy’s Hospital, London, graduating summa cum laude, with highest honors. He completed a residency at the LSU Eye Center in New Orleans and fellowships in corneal surgery at Baylor College of Medicine in Houston and in New York, New York on Project ORBIS. Dr. Slade is a Fellow of the American Academy of Ophthalmology and the American College of Surgeons. He is an active teacher of surgical techniques and has taught, lectured to, and certified over 8,000 surgeons on LASIK and lamellar refractive surgery. In 1991, along with Stephen Brint MD, he performed the first LASIK in the United States. Later he performed the first Custom LASIK ablation based on topography in the United States. He has since done tens of thousands of cases. Stephen Slade, M.D. has remained on the cutting edge, having the nation’s longest experience with Laser Cataract Surgery, all laser LASIK, accommodating IOLs (Crystalens) and the implantable contact lens (ICL). In fact, Dr. Slade was a lead investigator and presented the data to the FDA for panel approval for both the Crystalens and the implantable contact lens. Of unique note, Dr. Slade is considered a “surgeon’s surgeon”. Over 450 of his fellow eye surgeons have chosen him for their own eye surgery. He is an active researcher and the U.S. medical monitor for several new technologies including the Intralase laser for All Laser LASIK, the implantable corneal contact lens, and the Wavelight laser. He has received numerous awards including 11 named lectures, Refractive Surgeon of the Year, two China Service Medals, the Summit Technologies Pioneer of Refractive Surgery Award, the Casebeer Award and the Lans Lectureship. In 2007 Dr. Slade received the Barraquer Award, the high award from the largest society of refractive surgeons. The Barraquer Award is given only once a year to one doctor in the world. Dr. Slade was selected by his peers for both “Best Doctors” and “Best Doctors in America” and has received the Honor Award of the American Academy of Ophthalmology. He is a regular presenter at medical meetings and has received several “Best Speaker” awards and has twice won First Place at the American Society of Cataract and Refractive Surgery Film Festival. He has served on several Editorial Boards including the Journal of Refractive Surgery. Dr. Slade has produced many articles, book chapters, holds four patents or patents pending in the field and has authored nine textbooks on refractive surgery. He has been featured in numerous news segments aired on CBS, ABC and PBS as well as numerous national affiliate stations. Dr. Slade has been quoted in the New York Times and the Wall Street Journal as well as numerous local press stories. Dr. Slade was the featured surgeon on the Emmy Award winning PBS documentary “20/10 by 2010?” narrated by Walter Cronkite. Stephen Slade, MD was the first doctor in the United States to use the latest technology for cataract removal, the Femtosecond Laser. This high speed laser actually took over several of the steps in cataract surgery that were done by hand. We believe this will add precision and safety to the procedure. The results of this technique were presented at the largest meeting on cataracts, the American Society of Cataract and Refractive Surgery in April, 2010. Dr. Slade was elected the president of ACOS (American College of Ophthalmic Surgery) in January of 2011 and was also named a Leading Ophthalmologist in America by Becker’s ASC Review. Stephen Glenn Slade, M.D. is a specialist in Presbyopia correction, cataract surgery, LASIK, Implantable Contact Lenses, and refractive surgery. Dr. Slade is the current chairman of the board for AECOS (the American-European Congress of Ophthalmic Surgery). AECOS is an international organization of progressive ophthalmologists, dedicated to advancing vision care and improving patients’ quality of life through Innovation, Education and Advocacy. Dr. Slade is well known regionally, nationally, and internationally as a leader, innovator, and educator in the field of refractive surgery.
ALAN S. CRANDALL, M.D.
Dr. Alan Crandall graduated from the University of Utah, receiving his medical degree from the University of Utah School of Medicine. He completed his internship in surgery at the University of Pennsylvania Medical Center, as well as his residency and fellowship in ophthalmology at the Scheie Eye Institute, University of Pennsylvania. He joined the University of Utah Ophthalmology Department in 1981. Dr. Crandall is the John E. and Marva M. Warnock Presidential Endowed Chair; Senior Vice Chair of Ophthalmology and Visual Sciences; Director of Glaucoma and Cataract; and Senior Medical Director of Moran’s Global Outreach Division. Dr. Crandall is a Diplomat of the National Board of Medical Examiners as well as a member of the American Board of Ophthalmology. He also is a member of the American Society of Cataract and Refractive Surgery (ASCRS), American Glaucoma Society, the European Society of Cataract and Refractive Surgeons, and the International Intra-Ocular Implant Club. He is a past president of ASCRS. Alan S. Crandall focuses on the medical and surgical management of glaucoma and cataracts, as well as complicated anterior segment surgery. Dr. Crandall has experience with trabeculoplasty and laser cyclophotocoagulation. He is involved in numerous clinical research studies at the Moran Eye Center. Dr. Crandall, the senior medical director of Moran’s Global Outreach Division, lectures and performs sight-restoring surgery all over the world and was selected by Cataract and Refractive Surgery Today as one of the 50 most prominent opinion leaders. Dr. Crandall received the American Society of Cataract and Refractive Surgery (ASCRS) Foundation’s inaugural 2018 Chang Humanitarian Award. He is the only physician to receive humanitarian awards from all three major ophthalmology organizations: the 2016 American Glaucoma Society (AGS) Humanitarian Award; the 2014 American Academy of Ophthalmology (AAO) Humanitarian Award; and the 2013 ASCRS Humanitarian Award. Other awards include the Health Care Heroes Award for Excellence in Health Care – Community Outreach and the Vocational Excellence Award for Humanitarian Service by Rotary International.
DAVID D. EVELETH, JR., PH.D.
David Eveleth, PhD is currently Entrepreneur in Residence at CONNECT in San Diego and works with small biotechnology and pharmaceutical companies in the areas of ophthalmology, neuroscience, and regenerative medicine. Dr. Eveleth was the head of the Ophthalmology Medicines Development Group at Pfizer and has extensive experience in the development of ophthalmic therapeutics and devices.
DONALD P. TREMBLAY, ESQ.
Chief Legal Counsel
Donald P. Tremblay, Esq., serve’s as Intratus' Senior Vice-President for Strategic Planning and General Counsel.
Mr. Tremblay is a member of the company's Board of Directors.